Payment overview · 2025
General Payments
$633.74
30 reported records · 13 companies
Healthcare provider profile · identity verified
Federico Del Toro, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAFAYETTE, LA · NPI 1932118445
Verified facts
What the public records show
CMS Open Payments records show Federico Del Toro, M.D. received $633.74 in general payments during 2025 across 30 reported records.
Fresenius USA Marketing, Inc. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $131.32 | 20.7% | 6 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $105.17 | 16.6% | 5 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $100.06 | 15.8% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.94 | 8.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.42 | 6.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.37 | 6.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.72 | 5.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.74 | 5.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.29 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.52 | 3.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.08 | 3.0% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.61 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.50 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $633.74 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $131.32 | 6 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $105.17 | 5 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $100.06 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $54.94 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $38.42 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $37.02 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 326 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 278 | 69 |
| Gabapentin | Gabapentin | 269 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 58 |
| Furosemide | Furosemide | 148 | 38 |
| Lisinopril | Lisinopril | 145 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 20 |
| Metformin Hcl | Metformin Hcl | 126 | 27 |
| Potassium Chloride | Potassium Chloride | 120 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 24 |
| Carvedilol | Carvedilol | 110 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 19 |
| Alprazolam | Alprazolam | 99 | 18 |
| Famotidine | Famotidine | 95 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 14 |
| Glimepiride | Glimepiride | 89 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 20 |
| Trazodone Hcl | Trazodone Hcl | 81 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 79 | 19 |
| Losartan Potassium | Losartan Potassium | 78 | 19 |
| Levetiracetam | Levetiracetam | 75 | 15 |
| Eliquis | Apixaban | 74 | 16 |
| Meloxicam | Meloxicam | 74 | 19 |
| Omeprazole | Omeprazole | 72 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 71 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 23 |
| Pregabalin | Pregabalin | 64 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Clonidine Hcl | Clonidine Hcl | 56 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 17 |
| Linzess | Linaclotide | 54 | 11 |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Simvastatin | Simvastatin | 53 | 11 |
| Farxiga | Dapagliflozin Propanediol | 50 | 11 |
| Allopurinol | Allopurinol | 47 | 13 |
| Midodrine Hcl | Midodrine Hcl | 47 | suppressed |
| Azithromycin | Azithromycin | 46 | 37 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Ozempic | Semaglutide | 44 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | suppressed |
| Torsemide | Torsemide | 40 | 11 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 15 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 33 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Mupirocin | Mupirocin | 26 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 16 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Yuvafem | Estradiol | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $633.74 · 30 records | Fresenius USA Marketing, Inc. | Fabhalta, JARDIANCE, JYNARQUE, Korlym, Ozempic, PURIFIED CORTROPHIN GEL, TARPEYO, TAVNEOS, TZIELD, VELPHORO, Vanrafia, Veltassa, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error